Molecular Modeling in Drug Design
This book is a printed edition of the Special Issue Molecular Modeling in Drug Design that was published in Molecules
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Book Chapter |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 03403naaaa2201021uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_53851 | ||
| 005 | 20210211 | ||
| 020 | |a books978-3-03897-615-8 | ||
| 020 | |a 9783038976141 | ||
| 024 | 7 | |a 10.3390/books978-3-03897-615-8 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 100 | 1 | |a Wade, Rebecca |4 auth | |
| 700 | 1 | |a Salo-Ahen, Outi |4 auth | |
| 245 | 1 | 0 | |a Molecular Modeling in Drug Design |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (220 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book is a printed edition of the Special Issue Molecular Modeling in Drug Design that was published in Molecules | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a metadynamics | ||
| 653 | |a natural compounds | ||
| 653 | |a virtual screening | ||
| 653 | |a probe energies | ||
| 653 | |a molecular dynamics simulation | ||
| 653 | |a human ecto-5?-nucleotidase | ||
| 653 | |a neural networks | ||
| 653 | |a quantitative structure-activity relationship (QSAR) | ||
| 653 | |a artificial intelligence | ||
| 653 | |a allosterism | ||
| 653 | |a in silico screening | ||
| 653 | |a drug discovery | ||
| 653 | |a amyloid fibrils | ||
| 653 | |a mechanical stability | ||
| 653 | |a adenosine receptors | ||
| 653 | |a adenosine receptor | ||
| 653 | |a ligand binding | ||
| 653 | |a promiscuous mechanism | ||
| 653 | |a AutoGrid | ||
| 653 | |a dynamic light scattering | ||
| 653 | |a resultant dipole moment | ||
| 653 | |a density-based clustering | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a drug design | ||
| 653 | |a biophenols | ||
| 653 | |a enzymatic assays | ||
| 653 | |a all-atom molecular dynamics simulation | ||
| 653 | |a fragment screening | ||
| 653 | |a adenosine | ||
| 653 | |a docking | ||
| 653 | |a molecular docking | ||
| 653 | |a cosolvent molecular dynamics | ||
| 653 | |a turbidimetry | ||
| 653 | |a squalene synthase (SQS) | ||
| 653 | |a molecular recognition | ||
| 653 | |a protein-peptide interactions | ||
| 653 | |a extracellular loops | ||
| 653 | |a FimH | ||
| 653 | |a binding affinity | ||
| 653 | |a rational drug design | ||
| 653 | |a de novo design | ||
| 653 | |a hyperlipidemia | ||
| 653 | |a AR ligands | ||
| 653 | |a aggregation | ||
| 653 | |a property prediction | ||
| 653 | |a PPI inhibition | ||
| 653 | |a deep learning | ||
| 653 | |a proteins | ||
| 653 | |a quantitative structure-property prediction (QSPR) | ||
| 653 | |a protein protein interactions | ||
| 653 | |a boron cluster | ||
| 653 | |a target-focused pharmacophore modeling | ||
| 653 | |a ligand-protofiber interactions | ||
| 653 | |a structure-based drug design | ||
| 653 | |a scoring function | ||
| 653 | |a grid maps | ||
| 653 | |a solvent effect | ||
| 653 | |a adhesion | ||
| 653 | |a molecular dynamics | ||
| 653 | |a Traditional Chinese Medicine | ||
| 653 | |a steered molecular dynamics | ||
| 653 | |a interaction energy | ||
| 653 | |a EphA2-ephrin A1 | ||
| 653 | |a molecular modeling | ||
| 653 | |a method development | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1187 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/53851 |7 0 |z DOAB: description of the publication |